Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16681780 | 0.83 | HTT (0.38) | CYP2C19MEN1CYP1A2KMT2AHTT | |
| SCHEMBL2303474 | 0.76 | MEN1 (0.58) | CYP2C19MEN1CYP1A2KMT2AHTT | |
| SCHEMBL24311998 | 0.75 | MAPT (0.34) | — | |
| SCHEMBL25719706 | 0.71 | HDAC4 (0.33) | HTT | |
| SCHEMBL13889425 | 0.68 | CHRM2 (0.40) | CYP2C19MEN1CYP1A2KMT2ACYP2D6 | |
| SCHEMBL28289835 | 0.67 | TDP1 (0.45) | MEN1KMT2A | |
| SCHEMBL280106 | 0.67 | LMNA (0.43) | KMT2A | |
| SCHEMBL18403759 | 0.67 | KDM4E (0.35) | CYP2C19MEN1CYP1A2KMT2ACYP2D6 | |
| SCHEMBL29263881 | 0.67 | MAPT (0.45) | — | |
| SCHEMBL786364 | 0.67 | TDP1 (0.33) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | CYP2C19 1386/4885MEN1 559/4885CYP1A2 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.